A new study finds people working in “production” – fields such as manufacturing, welding and chemical operation – who are exposed to hazardous chemicals on the job, may have increased risk of developing ALS. People with ALS report higher occupational exposure to metals, particulate matter, volatile organic compounds and combustion pollutants prior to diagnosis.
There’s a huge urgency worldwide to find new therapies that help patients with amyotrophic lateral sclerosis (ALS), a fatal neurological disorder that causes people to eventually lose the ability to walk, talk, eat and breathe. In recognition of ALS Awareness Month, Dr. Deepti Lall shares why she’s optimistic about scientific advances for this fatal disease
Department of Rehabilitation and Human Performance will lead Mount Sinai in national clinical trial
Cedars-Sinai has been awarded $11.99 million by California’s stem cell agency to launch a clinical trial testing a potential gene and stem cell therapy for amyotrophic lateral sclerosis (ALS).
Research on a potential therapy for amyotrophic lateral sclerosis (ALS) that’s taking place in a University at Albany chemistry lab is showing promising results.
There is some hope on the horizon for patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. More than a dozen members of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) were authors on a study announcing the results showing promise in the fight against ALS that appeared in AANEM’s journal Muscle & Nerve.
KINGSTON, R.I. – June 25, 2020 – Doug Sawyer was diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, 11 years ago. His only muscles that still function are those that control eye movement.Despite his disability, Sawyer still works as an engineer from his home, designing electronics for Hayward Industries.